Ewing Sarcoma Market is Expected to Showcase a Significant Growth by 2032 | DelveInsight
March 29, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, March 29, 2023 (GLOBE NEWSWIRE) -- Ewing Sarcoma Market is Expected to Showcase a Significant Growth by 2032 | DelveInsight The Ewing sarcoma market is predicted to grow positively...
Ryan Davies Conducts CEO Chat with Leading Biotech IP Expert
January 20, 2023 03:01 ET
|
CancerVAX, Inc
LEHI, Utah, Jan. 20, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., a pre-clinical biotechnology company developing immunotherapy cancer treatments that use the body’s immune system to fight cancer,...
Global Bone Cancer Treatment Market to Reach $1.8 Billion by 2031: Says AMR
October 21, 2022 08:51 ET
|
Allied Market Research
Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Bone Cancer Treatment Market was estimated at $1.2 billion in 2021 and is...
AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
April 25, 2022 10:30 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., April 25, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., an AI driven clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced the...
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
March 10, 2022 16:05 ET
|
Salarius Pharmaceuticals, Inc.
Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing...
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
February 08, 2022 08:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
December 29, 2021 08:03 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
CancerVAX Announces Research Program to Develop Its First Immunotherapy Cancer Treatment
May 26, 2021 11:34 ET
|
CancerVAX, Inc
SANTA BARBARA, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced that it has...